NorthSea's orziloben nears Q3 readout in rare liver disease IFALD
A 36-patient Phase 2 trial testing whether orziloben eases cholestasis and fibrosis in intestinal failure-associated liver disease is set to read out with no approved therapy in the field to beat.
Executive Summary
- A small, industry-sponsored Phase 2 trial is approaching a readout that will test whether orziloben improves several liver-disease markers in a rare, orphan-designated condition with no approved treatment.
- NorthSea Therapeutics recently strengthened its board with a hepatology-focused executive as it positions orziloben for late-stage development, alongside orphan and rare pediatric disease designations from regulators in the US and Europe.
- The disease has essentially no direct competitive field: the only other identified trial in the same indication studies an unrelated mechanism, leaving orziloben without a validated precedent to beat or a rival readout to react to.
- Enrollment has held at target with no protocol churn, and the sponsor has completed every prior trial it has run, pointing to execution risk sitting lower than timing and endpoint risk for this readout.
The catalyst
NorthSea Therapeutics guided investors to a Phase 2 readout for orziloben in the third quarter of 2026, tied to the trial registered as NCT05919680. The company disclosed the timing in a March 31, 2026 release announcing the addition of Pam Vig, Ph.D., to its board as it moves orziloben "into late-stage development, with the aim of treating intestinal failure associated liver disease (IFALD) patients worldwide," said Sander Slootweg, the company's board chair. Vig, who co-founded Mirum Pharmaceuticals and led clinical research at Tobira Therapeutics, said she believes orziloben "has the potential to be an effective first-in-class treatment for people living with IFALD". That assessment comes from a company-affiliated board member, not an independent registry finding. NCT05919680+1A Study of NST-6179 in Subjects With Intestinal Failure-Associated Liver Disease (IFALD).NCT05919680NorthSea Therapeutics Bolsters Board, as Orziloben Moves into Late-stage DevelopmentMar 31, 2026
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
The trial design
The 36-patient, randomized trial enrolls adults on parenteral nutrition for at least six months who have persistent liver enzyme elevation or elevated bilirubin consistent with IFALD, excluding those with cirrhosis or more advanced hepatic impairment. Orziloben is administered orally against a placebo comparator, and the design carries six primary endpoints spanning pharmacodynamic effects on hepatic cholestasis (bilirubin, ALP, GGT), fibrosis markers (ELF, Pro-C3, FIB-4), inflammation, steatosis, pharmacokinetics, and safety and tolerability. The trial's primary completion date is listed as June 30, 2025, and it remains in Recruiting status with a registry-tracked protocol history showing only an eligibility-criteria update and a status change from Not-yet-recruiting to Recruiting, with no primary-completion-date amendments or endpoint changes. NCT05919680A Study of NST-6179 in Subjects With Intestinal Failure-Associated Liver Disease (IFALD).NCT05919680
The regulatory backdrop
Orziloben carries orphan drug designation from both the FDA and the European Medicines Agency, and has separately received rare pediatric disease designation from the FDA, the company disclosed. Those designations reflect the FDA's and EMA's assessment of an unmet need in a rare disease population; they do not signal an expectation of approval or a completed regulatory review. No FDA approval record exists for orziloben in any indication as of the current disclosures. NorthSeaNorthSea Therapeutics Bolsters Board, as Orziloben Moves into Late-stage DevelopmentMar 31, 2026
The competitive frame
IFALD carries essentially no comparable pipeline. A broader search of trials in the indication surfaces only one other active study, testing an EDTA lock solution to prevent catheter occlusions in children with intestinal failure, a mechanism that does not address liver disease and is not a direct comparator. No competitor trial shares orziloben's target or mechanism class, and no completed same-drug or same-mechanism trial exists to benchmark against. That leaves the field without a validated disease-modifying mechanism on record: a result showing consistent improvement across the cholestasis, fibrosis, and steatosis measures, with a safety profile that supports continued dosing, would be the signal that this program has cleared where an unproven field previously offered nothing to measure against.
Operational signal
The trial's enrollment target has stayed unchanged at 36 patients, a hold the operational model reads as typical and not a distress signal. NorthSea has completed all five of its other trials with no terminations, and this is one of two active trials on the company's registry-tracked portfolio. That combination points execution risk away from the sponsor's operating discipline and toward the endpoint and timing questions the Q3 2026 window will resolve.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.